Merck KGaA announced its second‑quarter 2026 financial results, showing a notable improvement in adjusted earnings before interest, tax, depreciation and amortisation (adjusted EBITDA). The adjusted EBITDA reached €1.6 billion, representing a 9.4% increase year‑on‑year, primarily driven by strong performance in the life‑science and electronics divisions. Net sales for the quarter grew 3.4% to €5.43 billion, although the healthcare segment experienced a 3.4% decline in sales.
When one‑off items are included, the company’s net profit fell nearly 25% to €494 million. The decline was chiefly attributed to depreciation costs linked to Merck’s acquisition of SpringWorks Therapeutics, completed in 2025, and higher restructuring expenses associated with an ongoing operational overhaul.
Despite the profit dip, Merck raised its full‑year outlook. The revised guidance now projects adjusted EBITDA in the range of €5.9 billion to €6.3 billion, up from the previous €5.7 billion‑€6.1 billion range. Net sales guidance was also increased to €21.0 billion‑€21.8 billion, compared with the earlier €20.4 billion‑€21.4 billion range. The company highlighted that life‑science is expected to remain a key earnings driver for the remainder of the fiscal year.